SCYNEXIS Stock

SCYNEXIS Net Debt/Equity

The Net Debt to Equity Ratio of SCYNEXIS (SCYX) as of Aug 9, 2026 is -0.83. In the previous year, Net Debt to Equity Ratio was -0.85 — a change of -2.86% (higher).

Net Debt/Equity

-0.83

YoY

-2.86%

Last updated:

Net Debt to Equity Ratio of SCYNEXIS is 2026 -0.83 . Net Debt to Equity Ratio of SCYNEXIS was 2025 -0.85 . It decreases by -2.86% higher compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Net Debt to Equity Ratio of SCYNEXIS is -0.83 in 2026.

Net Debt to Equity Ratio of SCYNEXIS changed from -0.85 to -0.83, representing a -2.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's SCYNEXIS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — SCYNEXIS

All Key Metrics — SCYNEXIS